Bio & Pharma
Syntekabio expands to US with local CRO
The deal with Target Health seeks to boost the customer base for AI-based drug development solutions
By Jun 20, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Macquarie eyes its 1st Korean data center valued around $722 mn
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
SK Inc. in talks to sell Pharmteco’s US CDMO plant to Novo Nordisk
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Syntekabio expands to US with local CRO](https://www.kedglobal.com/data/ked/image/2023/06/20/ked202306200009.602x.0.jpg)
South Korean artificial intelligence (AI) drugmaker Syntekabio Inc. has partnered up with a US clinical research organization (CRO) to enter the world’s largest market for drug development.
Syntekabio aims to boost its potential global customer base and its network in America.
Syntekabio on Monday said it signed a memorandum of understanding on business development with the New York-based Target Health, a CRO founded in 1993 by former Pfizer executive Jules Mitchell that has supported over 1,000 clinical trials and licensing processes.
This is Syntekabio’s first MOU with an American company.
The two companies will bring Sintekabio’s AI-based drug cloud solution STBcloud and development platform candidate DeepMatcher to the U.S. market.
STB Cloud is a new drug development platform whose biggest strength is simplification and automation of the drug discovery process available anytime and anywhere. DeepMatcher needs just four weeks to select effective drug candidates from a billion compounds and another four weeks to deliver leading candidates, Sintekabio said.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Artificial intelligenceSyntekabio launches new drug development platform STB Cloud in US
Dec 19, 2022 (Gmt+09:00)
1 Min read
Comment 0
LOG IN